Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187943 | 1.00 | SLC18A3 (0.76) | SLC18A3ALDH1A1FUCA1HTR1ADRD2 | |
| SCHEMBL2187946 | 1.00 | SLC18A3 (0.76) | SLC18A3ALDH1A1FUCA1HTR1ADRD2 | |
| SCHEMBL2191616 | 0.99 | SLC18A3 (0.74) | SLC18A3ALDH1A1FUCA1HTR1ADRD2 | |
| SCHEMBL2191620 | 0.99 | SLC18A3 (0.74) | SLC18A3ALDH1A1FUCA1HTR1ADRD2 | |
| SCHEMBL2191623 | 0.99 | SLC18A3 (0.74) | SLC18A3ALDH1A1FUCA1HTR1ADRD2 | |
| SCHEMBL13229630 | 0.87 | FUCA1 (0.61) | SLC18A3ALDH1A1FUCA1SIGMAR1 | |
| SCHEMBL8522225 | 0.86 | SLC18A3 (0.69) | SLC18A3SIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL23535598 | 0.82 | SLC18A3 (0.64) | SLC18A3ALDH1A1FUCA1SIGMAR1 | |
| SCHEMBL23535597 | 0.82 | SLC18A3 (0.64) | SLC18A3ALDH1A1FUCA1SIGMAR1 | |
| SCHEMBL23535599 | 0.82 | SLC18A3 (0.64) | SLC18A3ALDH1A1FUCA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351738-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL | Sumitomo Chemical Company, Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | TEAD4, TEAD3, TEAD2 | SLC18A3 1096/4885ALDH1A1 93/4885FUCA1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.